What were the characteristics of the study population, relative to prior regimens?
All patients had disease that had relapsed after two or more prior therapies and/or was refractory to two or more prior therapies. In the phase 2 study, approximately 94% of patients (46 of 49) had received 2 to 4 prior regimens. 30.6% of patients (15 of 49) had undergone at least 1 prior transplant.
